Abstract
Mutations in PINK1 and PARK2 cause autosomal recessive parkinsonism, a neurodegenerative disorder that is characterized by the loss of dopaminergic neurons. To discover potential therapeutic pathways, we identified factors that genetically interact with Drosophila park and Pink1. We found that overexpression of the translation inhibitor Thor (4E-BP) can suppress all of the pathologic phenotypes, including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants. Rapamycin also ameliorated mitochondrial defects in cells from individuals with PARK2 mutations. Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant mutations in LRRK2. We also found that loss of the Drosophila LRRK2 homolog activated 4E-BP and was also able to suppress Pink1 and park pathology. Thus, in conjunction with recent findings, our results suggest that pharmacologic stimulation of 4E-BP activity may represent a viable therapeutic approach for multiple forms of parkinsonism.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abou-Sleiman, P.M., Muqit, M.M. & Wood, N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7, 207–219 (2006).
Farrer, M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7, 306–318 (2006).
Clark, I.E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162–1166 (2006).
Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157–1161 (2006).
Yang, Y. et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA 103, 10793–10798 (2006).
Exner, N. et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27, 12413–12418 (2007).
Whitworth, A.J., Wes, P.D. & Pallanck, L.J. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov. Today 11, 119–126 (2006).
Whitworth, A.J. et al. Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin. Dis. Model Mech. 1, 168–174 (2008).
Tain, L.S. et al. Drosophila HtrA2 is dispensable for apoptosis but acts downstream of PINK1 independently from Parkin. Cell Death Differ. 16, 1118–1125 (2009).
Poole, A.C. et al. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. USA 105, 1638–1643 (2008).
Yang, Y. et al. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc. Natl. Acad. Sci. USA 105, 7070–7075 (2008).
Mortiboys, H. et al. Mitochondrial function and morphology are impaired in parkin-mutant fibroblasts. Ann. Neurol. 64, 555–565 (2008).
Greene, J.C., Whitworth, A.J., Andrews, L.A., Parker, T.J. & Pallanck, L.J. Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis. Hum. Mol. Genet. 14, 799–811 (2005).
Clemens, M.J. Translational regulation in cell stress and apoptosis. Roles of the eIF4E binding proteins. J. Cell. Mol. Med. 5, 221–239 (2001).
Holcik, M. & Sonenberg, N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 6, 318–327 (2005).
Richter, J.D. & Sonenberg, N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433, 477–480 (2005).
Gingras, A.C., Raught, B. & Sonenberg, N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913–963 (1999).
Gingras, A.C., Raught, B. & Sonenberg, N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15, 807–826 (2001).
Wullschleger, S., Loewith, R. & Hall, M.N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006).
Bernal, A. & Kimbrell, D.A. Drosophila Thor participates in host immune defense and connects a translational regulator with innate immunity. Proc. Natl. Acad. Sci. USA 97, 6019–6024 (2000).
Kapahi, P. et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14, 885–890 (2004).
Teleman, A.A., Chen, Y.W. & Cohen, S.M. 4E-BP functions as a metabolic brake used under stress conditions, but not during normal growth. Genes Dev. 19, 1844–1848 (2005).
Tettweiler, G., Miron, M., Jenkins, M., Sonenberg, N. & Lasko, P.F. Starvation and oxidative stress resistance in Drosophila are mediated through the eIF4E-binding protein, d4E-BP. Genes Dev. 19, 1840–1843 (2005).
Yamaguchi, S. et al. ATF4-mediated induction of 4E-BP1 contributes to pancreatic beta cell survival under endoplasmic reticulum stress. Cell Metab. 7, 269–276 (2008).
Holcik, M., Sonenberg, N. & Korneluk, R.G. Internal ribosome initiation of translation and the control of cell death. Trends Genet. 16, 469–473 (2000).
Imai, Y. et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432–2443 (2008).
Whitworth, A.J. et al. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 102, 8024–8029 (2005).
Puig, O., Marr, M.T., Ruhf, M.L. & Tjian, R. Control of cell number by Drosophila FOXO: downstream and feedback regulation of the insulin receptor pathway. Genes Dev. 17, 2006–2020 (2003).
Southgate, R.J. et al. FOXO1 regulates the expression of 4E-BP1 and inhibits mTOR signaling in mammalian skeletal muscle. J. Biol. Chem. 282, 21176–21186 (2007).
Murphy, C.T. et al. Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature 424, 277–283 (2003).
McElwee, J.J. et al. Evolutionary conservation of regulated longevity assurance mechanisms. Genome Biol. 8, R132 (2007).
Giannakou, M.E. et al. Long-lived Drosophila with overexpressed dFOXO in adult fat body. Science 305, 361 (2004).
Hwangbo, D.S., Gershman, B., Tu, M.P., Palmer, M. & Tatar, M. Drosophila dFOXO controls lifespan and regulates insulin signaling in brain and fat body. Nature 429, 562–566 (2004).
Beretta, L., Gingras, A.C., Svitkin, Y.V., Hall, M.N. & Sonenberg, N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15, 658–664 (1996).
Brunn, G.J. et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99–101 (1997).
Burnett, P.E., Barrow, R.K., Cohen, N.A., Snyder, S.H. & Sabatini, D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95, 1432–1437 (1998).
Gloeckner, C.J. et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223–232 (2006).
West, A.B. et al. Parkinson's disease–associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102, 16842–16847 (2005).
Gingras, A.C. et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852–2864 (2001).
Müftüoglu, M. et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord. 19, 544–548 (2004).
King, M.A. et al. Rapamycin inhibits polyglutamine aggregation independently of autophagy by reducing protein synthesis. Mol. Pharmacol. 73, 1052–1063 (2008).
Wyttenbach, A., Hands, S., King, M.A., Lipkow, K. & Tolkovsky, A.M. Amelioration of protein misfolding disease by rapamycin: translation or autophagy? Autophagy 4, 542–545 (2008).
Scott, R.C., Schuldiner, O. & Neufeld, T.P. Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev. Cell 7, 167–178 (2004).
Levine, B. & Klionsky, D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 6, 463–477 (2004).
Singh, S.P., Coronella, J.A., Benes, H., Cochrane, B.J. & Zimniak, P. Catalytic function of Drosophila melanogaster glutathione S-transferase DmGSTS1-1 (GST-2) in conjugation of lipid peroxidation end products. Eur. J. Biochem. 268, 2912–2923 (2001).
Li, Y. et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 12, 826–829 (2009).
Greene, J.C. et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 100, 4078–4083 (2003).
Jünger, M.A. et al. The Drosophila forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J. Biol. 2, 20 (2003).
Miron, M. et al. The translational inhibitor 4E-BP is an effector of PI(3)K/Akt signaling and cell growth in Drosophila. Nat. Cell Biol. 3, 596–601 (2001).
De Vos, K.J. & Sheetz, M.P. Visualization and quantification of mitochondrial dynamics in living animal cells. Methods Cell Biol. 80, 627–682 (2007).
Acknowledgements
We would like to thank L. Pallanck, P. Ingham and L. Partridge for critical reading of the manuscript and discussions. We would also like to thank J. Chung, S. Birman, L. Partridge, N. Sonenberg and T. Neufeld for Drosophila lines, H. Beneš for the antibody to GstS1 and I. Bjedov for Atg5 qPCR primer sequences. We also acknowledge the Department of Biomedical Science Centre for Electron Microscopy for technical assistance. This work was supported by grants from the Parkinson's Disease Society UK (G-4063 and G-0713 to A.J.W. and G-0715 to O.B.) and the Royal Society and Wellcome Trust (081987) to A.J.W. The MRC Centre for Developmental and Biomedical Genetics is supported by grant G070091. The Wellcome Trust (grant number GR077544AIA) supports the Light Microscopy Facility.
Author information
Authors and Affiliations
Contributions
L.S.T., H.M., R.N.T., E.Z. and A.J.W. designed and conducted the experiments and analyzed the data. L.S.T. and A.J.W. prepared the figures and wrote the manuscript. A.J.W. and O.B. supervised the project, and contributed to experimental design and data analysis.
Corresponding author
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3 (PDF 1686 kb)
Rights and permissions
About this article
Cite this article
Tain, L., Mortiboys, H., Tao, R. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12, 1129–1135 (2009). https://doi.org/10.1038/nn.2372
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn.2372
This article is cited by
-
Key genes and convergent pathogenic mechanisms in Parkinson disease
Nature Reviews Neuroscience (2024)
-
Crossregulation of rapamycin and elaiophylin biosynthesis by RapH in Streptomyces rapamycinicus
Applied Microbiology and Biotechnology (2022)
-
A transition to degeneration triggered by oxidative stress in degenerative disorders
Molecular Psychiatry (2021)
-
Preliminary Findings on Proline-Rich Protein 14 as a Diagnostic Biomarker for Parkinson’s Disease
NeuroMolecular Medicine (2021)
-
Identification of PP2A and S6 Kinase as Modifiers of Leucine-Rich Repeat Kinase-Induced Neurotoxicity
NeuroMolecular Medicine (2020)